N/A
Completed N=73
Association of Type of Anesthetic and Outcomes in Transfemoral Aortic Valve Replacement
Source: ClinicalTrials.gov NCT02786264 ↗Enrolled (actual)
73
Serious AEs
—
Results posted
Apr 2023
Primary outcomePrimary: Procedure Length — 114.5; 100 minutes
Summary
This study proposes to perform a descriptive analysis and pilot observational study looking at the types and quantity of anesthetic agents used and their associations with outcomes among patients scheduled to receive transfemoral aortic valve replacements (TAVR) at Yale New Haven Hospital (YNHH).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Procedure Length |
114.5; 100 | — |
| SECONDARY ICU Length of Stay |
1; 1 | — |
| SECONDARY Rate of Conversion to General Anesthesia |
31; 38; 3; 1 | — |
| SECONDARY Hospital Length of Stay |
2; 2 | — |
| SECONDARY Delirium Incidence |
34; 38; 0; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who underwent TAVR at YNHH under planned conscious sedation with monitored anesthetic care
Exclusion Criteria
- Patients who received monitored anesthesia care without the receipt of any study intervention drug (propofol, fentanyl, midazolam, or dexmedetomidine).
Data sourced from ClinicalTrials.gov (NCT02786264). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.